Obseva gained more than 15% in morning trade Thursday after it advanced some information from presentations to be given at the European Society of Human Reproduction and Embryology (ESHRE) 2017 Annual Meeting, taking place July 2-5 in Geneva, Switzerland. Among highlights, the company said phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART (assisted reproductive therapy). Nolasiban is an oral oxytocin receptor antagonist with the potential to decrease uterine contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation, all of which may increase the chance of successful pregnancy and live-birth among patients undergoing ART.
The company also said non-clinical results of OBE022 for preterm labor demonstrate both monotherapy/combination potential. OBE022 is the company’s selective prostaglandin F2alpha receptor antagonist, which is designed to control preterm labor.